Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

China flag China · Delayed Price · Currency is CNY
20.34
+0.33 (1.65%)
Mar 10, 2026, 1:02 PM CST
-14.43%
Market Cap 7.96B
Revenue (ttm) 1.38B
Net Income (ttm) -16.97M
Shares Out 397.73M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE 63.86
Dividend 0.30 (1.48%)
Ex-Dividend Date n/a
Volume 791,898
Average Volume 1,230,441
Open 20.10
Previous Close 20.01
Day's Range 20.10 - 20.47
52-Week Range 19.58 - 26.77
Beta 0.88
RSI 39.67
Earnings Date Apr 23, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 2,754
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688105
Full Company Profile

Financial Performance

In 2025, Nanjing Vazyme Biotech's revenue was 1.38 billion, a decrease of -0.00% compared to the previous year's 1.38 billion. Losses were -16.97 million, -6.21% less than in 2024.

Financial Statements

News

There is no news available yet.